Raymond James & Associates’s Faeth Therapeutics FTH Stock Holding History

Raymond James & Associates’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$12K	Buy	1,000 +300	+43%	+$3.66K	﹤0.01%	3965
2024 Q2	$8.68K	Hold	700	–	–	﹤0.01%	3933
2024 Q1	$14.7K	Hold	700	–	–	﹤0.01%	3886
2023 Q4	$9.69K	Hold	700	–	–	﹤0.01%	3795
2023 Q3	$11.2K	Hold	700	–	–	﹤0.01%	3757
2023 Q2	$16K	Hold	700	–	–	﹤0.01%	3786
2023 Q1	$21K	Sell	700 -250	-26%	-$7.41K	﹤0.01%	3798
2022 Q4	$28.3K	Hold	950	–	–	﹤0.01%	3767
2022 Q3	$29K	Hold	950	–	–	﹤0.01%	3762
2022 Q2	$43K	Buy	950 +300	+46%	+$11.2K	﹤0.01%	3806
2022 Q1	$30K	Buy	+650	New	+$51.7K	﹤0.01%	3964

Other funds holding FTH

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Raymond James & Associates's FTH Position: Q3 2024 in Review

Raymond James & Associates increased its Faeth Therapeutics (FTH) stake by 43% in Q3 2024, buying an estimated $3.66K and bringing the position to 1,000 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #3965.

Raymond James & Associates first reported a position in FTH in Q1 2022 and has held it in 11 quarters since. The position peaked at $43K in Q2 2022. 19 funds tracked by Wall St. Rank hold FTH as of Q3 2024.

Raymond James & Associates held 1,000 shares of Faeth Therapeutics worth $12K as of Q3 2024.
Raymond James & Associates bought 300 Faeth Therapeutics shares in Q3 2024, an estimated $3.66K.
Faeth Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3965 holding.
Raymond James & Associates first reported a position in Faeth Therapeutics in Q1 2022 and has held it in 11 quarters since.
Raymond James & Associates's Faeth Therapeutics position peaked at $43K in Q2 2022.
19 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.